A study exploring the potential of selenium incorporated in dairy proteins to improve health and reduce the risk of colon cancer.

Completed

• Conditions: Bowel Cancer; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12605000310662
• Lead Sponsor: Flinders Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Participants will be healthy, with no active bowel disease, or a previous history of adenoma removal >6 months ago, with plasma selenium at or below 95ug/dL.

Exclusion Criteria

Any allergy or intolerance to milk/dairy products plasma Se above the 95th percentile of the current population (i.e. >95ug/dl), evidence of any active mucosal bowel disease, eg colitis, or of malabsorption, no evidence of any other active clinical disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of plasma glutathione peroxidase (GSPx) taken at the beginning and end of each intervention[At the beginning and end of each treatment (Week 0 and week 8).]

Secondary Outcome Measures

Name	Time	Method
evel of biomarkers in rectal epithelium including Glutathione (GSH), Glutathione Peroxidase (GSPx), histological PCNA cell proliferation and apoptosis rates, p53 immunohistochemical staining.[Taken at the beginning and end of each intervention (Wk 0 & week 8).];Level of biomarkers in blood including plasma selenium and/or erythrocyte Se, GSH, selenoprotein P, plasma levels of thyroid hormones T3 and T4, ).[Taken at the beginning and end of each intervention (Wk 0 & week 8).]